Recombinant Full Length Human RPA2 Protein, C-Flag-tagged

• Cat.No.: RPA2-1430HFL
• Product Overview: Recombinant Full Length Human RPA2 Protein, fused to Flag-tag at C-terminus, was expressed in Mammalian cells.

Specification

• Description: This gene encodes a subunit of the heterotrimeric Replication Protein A (RPA) complex, which binds to single-stranded DNA (ssDNA), forming a nucleoprotein complex that plays an important role in DNA metabolism, being involved in DNA replication, repair, recombination, telomere maintenance, and co-ordinating the cellular response to DNA damage through activation of the ataxia telangiectasia and Rad3-related protein (ATR) kinase. The RPA complex protects single-stranded DNA from nucleases, prevents formation of secondary structures that would interfere with repair, and co-ordinates the recruitment and departure of different genome maintenance factors. The heterotrimeric complex has two different modes of ssDNA binding, a low-affinity and high-affinity mode, determined by which oligonucleotide/oligosaccharide-binding (OB) domains of the complex are utilized, and differing in the length of DNA bound. This subunit contains a single OB domain that participates in high-affinity DNA binding and also contains a winged helix domain at its carboxy terminus, which interacts with many genome maintenance protein. Post-translational modifications of the RPA complex also plays a role in co-ordinating different damage response pathways.
• Source: Mammalian cells
• Species: Human
• Tag: Flag
• Form: 25 mM Tris HCl, pH 7.3, 100 mM glycine, 10% glycerol.
• Molecular Mass: 29.1 kDa
• AA Sequence: MWNSGFESYGSSSYGGAGGYTQSPG GFGSPAPSQAEKKSRARAQHIVPCT ISQLLSATLVDEVFRIGNVE ISQVTIVGIIRHAEKAPTNIVYKID DMTAAPMDVRQWVDTDDTSSENTVV PPETYVKVAGHLRSFQNKKS LVAFKIMPLEDMNEFTTHILEVINA HMVLSKANSQPSAGRAPISNPGMSE AGNFGGNSFMPANGLTVAQN
  QVLNLIKACPRPEGLNFQDLKNQLK HMSVSSIKQAVDFLSNEGHIYSTVD DDHFKSTDAESGPTRTRPLEQKLIS EEDLAANDILDYKDDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade.
• Concentration: >50 ug/mL as determined by microplate BCA method.
• Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps.
• Protein Families: Druggable Genome, Stem cell - Pluripotency
• Protein Pathways: DNA replication, Homologous recombination, Mismatch repair, Nucleotide excision repair

Gene Information

• Gene Name: RPA2 replication protein A2 [ Homo sapiens (human) ]
• Official Symbol: RPA2
• Synonyms: REPA2; RPA32; RP-A p32; RP-A p34
• Gene ID: 6118
• mRNA Refseq: NM_002946.5
• Protein Refseq: NP_002937.1
• MIM: 179836
• UniProt ID: P15927

Reviews

12/21/2020

This commitment ensures that I have access to the most advanced and reliable protein available, enhancing the integrity and impact of my experiments.

03/30/2020

The RPA2 protein exhibits exceptional quality, making it an ideal choice to meet my experimental requirements.

07/19/2018

the manufacturer's customer-centric approach highlights their focus on ensuring my satisfaction.

Q&As

How might RPA2 be targeted for cancer therapy?

Targeting RPA2 with specific inhibitors could disrupt DNA repair mechanisms in cancer cells, rendering them more susceptible to treatments like chemotherapy or radiation therapy.

How does RPA2 contribute to the maintenance of telomeres?

RPA2 participates in the protection and maintenance of telomeres, the protective caps at the end of chromosomes, thereby contributing to cellular longevity and genomic stability.

Are there any known side effects or challenges associated with targeting RPA2 in therapy?

Targeting RPA2 in therapy may pose challenges, as its essential role in normal cellular processes raises concerns about potential side effects. Careful modulation is crucial.

Can RPA2 be targeted for therapeutic purposes beyond cancer treatment?

Yes, exploring RPA2 as a therapeutic target extends to conditions where genomic stability is compromised, such as certain genetic disorders and autoimmune diseases.

Are there any ongoing clinical trials involving RPA2 in cancer treatment?

Information about specific clinical trials should be checked, but the potential use of RPA2 as a target for cancer therapy is an area of active research.